Jerrell Shelton: Yes. I will begin and then Robert can conclude on that question, David. But you are right, there is a lot of EBITDA potential in the SG&A. And that SG&A is inflated because of the number of projects that we have going on. These are all customer-driven, market-driven projects with great potential. And – but they do have an impact as they are under development on the SG&A, but the potential is enormous. Robert?
Robert Stefanovich: Yes. I will say I may start – maybe first with some of the earlier investments we have made that we talked about. Some of those investments are starting to pay-off now. We talked about the biostorage, bioservices revenue that grew 26%, and then also, obviously, building our core solutions in terms of the revenue growth on the commercial side. Noteworthy there is the initiative that we have related to our Cryoport Elite Shipper, supporting Sarepta’s commercial launch. So, these are initiatives that you have seen over the last years in terms of building out some of these competencies. And then we talked about building out the overall global infrastructure. And really, if you look at the market that we are in and the expected growth that we are seeing, just based on discussions with the clients that we are currently serving in clinical trials and commercial launches, we do know that this will ultimately drive significant revenue.
And you are absolutely right. As you see that revenue grow and as you see us leveraging the assets and the capabilities, specifically in the cell and gene therapy space, you will see that EBITDA margin grow with that as well. So, we are very mindful of cash. We are very mindful of spending and ensuring that we have the right ROIs. And it’s on our mind and certainly on the investors’ minds as you stated. But at the same time, we see a significant opportunity for us, really, to further bolster our leadership position and to capture more wallet share from these customers that are poised to grow quite significantly over the next years.
David Larsen: Thanks very much.
Operator: There are no further questions at this time. Jerry, please proceed with the closing remarks.
Jerrell Shelton: First of all, I want to thank all of you for joining the call today and the robust question-and-answer period. There were good questions and gave us a chance to talk about some very important things. In closing, our third quarter results were in line with our expectations, showing some growth aspects, particularly in commercial revenue. At the same time, Cryoport has continued to execute on its corporate strategy, increasing its market presence and capabilities through meaningful partnerships and acquisitions. By continuing to execute on this strategy, we believe Cryoport will emerge as an even stronger company that is well positioned to achieve long-term profitable growth. We thank you for joining us today. We appreciate your continuing support and interest in our company, and we look forward to updating you on our progress again for the fourth quarter very soon. So, have a good evening. Thank you very much.
Operator: Ladies and gentlemen, this concludes today’s conference. Thank you for your participation. You may now disconnect.
